CClinicalTrials.gg
CompletedNCT03637946Updated Feb 5, 2020

Release of Organic Components of a GIOMER in Non-carious Cervical Lesion Restorations

An interventional study of Device: SHOFU beautifil II LS in Non-carious Cervical Lesions, sponsored by Federal University of Minas Gerais. Completed at 1 site in Brazil. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Federal University of Minas Gerais · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

To evaluated the clinical performance of composite resin restorations, considering also the evaluation of release of resin components into saliva and the presence cytokines in gingival fluid. Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were use. For in vitro assays, adhesive and resin specimens are being preparing for assessing the monomers degree of conversion (by FTIR), sorption and solubility and release of resinous components in ethanol and Ringer solutions (through a gas chromatography and mass spectroscopy - GC-MS). In the longitudinal clinical study clinical performance of restorations and periodontal response were evaluate.

Read the detailed description

Release of components of a resin composite system containing pre-reagent vitreal particles: laboratory and patient studies. The objectives of this study was to evaluate physical and chemical properties of a methacrylate-based restorative system regarding to the release of resin components to the storage medium, to evaluate the clinical performance of composite resin restorations, considering also the evaluation of release of resin components into saliva and the presence of cytokines in gingival crevicular fluid. Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were use. For in vitro assays, adhesive and resin specimens are being preparing for assessing the monomers degree of conversion (by FTIR), sorption and solubility and release of resinous components in ethanol and Ringer solutions (through a gas chromatography and mass spectroscopy - GC-MS). In the longitudinal clinical study, patients who present a NCCL with restorative need were selecting. Prior to treatment, there will be periodontal evaluation, saliva and gingival crevicular fluid collection (controls). The lesions were restoring with the restorative system. After 10 min,7 days, 1 and 6 months, clinical performance of restorations and periodontal response were evaluate according to the criterion FDI. Additionally, in all of these evaluation periods samples of saliva and crevicular fluid are being collecting. Saliva samples will be analyze by GC-MS to identify the eventual presence of organic components derived from the restoration. The crevicular fluid samples were analyzing using ELISA for identification and quantification of interleukins.

02

Conditions studied

  • Non-carious Cervical Lesions

Keywords

  • Resin composite
  • clinical trial
  • biocompatibility
  • cytokines
03

In context

Uterine Cervical Diseases

53 studies on the registry are indexed under Uterine Cervical Diseases; 11 are open to participants now.

This study's enrollment of 10 is below the median of 48 across 40 interventional studies indexed under Uterine Cervical Diseases.

Browse Uterine Cervical Diseases studies →

Lead sponsor

Federal University of Minas Gerais is the lead sponsor of 150 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Over 18 years of age; Systemically healthy; Non-smoking;
  • With good oral hygiene;
  • Absent irreversible pulpal alteration;
  • With the presence of a non-carious cervical lesion (LCNCs) that needs to be restored. This lesion should be non-carious, non-retentive, with at least 1 mm and up to 3 mm depth, should involve both enamel and dentin of vital teeth without mobility, and present hypersensitivity;
  • Presence a natural tooth of the same position of the restored tooth, but in the opposite arch of the same jaw to be considered for the positive control;
  • Periodontal parameters : Depth Probing (PS), Visible Plaque Index (IPV), Gingival Index (GI) and Probing Bleed Index (SS). The normal included were: PS = 1 to 3 mm, GI = 0, IPV = score 0 e SS = score 0.

Exclusion criteria

Exclusion Criteria:

  • With severe systemic alteration;
  • In the use of antibiotics and anti-inflammatories in the last three months;
  • With periodontium with periodontal parameters different from those established in the inclusion criteria.
  • Individuals with clinical signs of parafunctional habits;
  • Smoking;
  • Individuals who have performed other restorations in the last 12 months;
  • Pregnant women and infants;
  • Periodontal sites that presented bleeding during crevicular fluid collection or sites that prevent proper collection of clinical parameters.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    SHOFU Beautifil II LS

    Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)

    Other: Device: SHOFU beautifil II LS

Interventions

  • OtherDevice: SHOFU beautifil II LS

    Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions

06

What researchers measure

Primary outcomes

  1. FDI criteria

    The evaluation of the quality of the restoration will be evaluated using the FDI criteria and will be performed by two trained examiners at baseline and follow-up visits.The criteria has score given for each property with range from 1 to 5. Clinical assessments (Esthetic properties:surface brightness, surface and marginal color, color and translucency and anatomical form, Functional properties: marginal adaptation, fracture of material and retention, and Biological Properties: postoperative hypersensitivity, recurrence of caries, tooth integrity and adjacent mucosa)

    Time frame: Up to 6 months

Secondary outcomes

  1. Clinical parameters: visible plaque index (IPV)

    registered presence (score 1) or absence (score 0) of bacterial plaque without the use of probe, after drying the dental surface with compressed air.

    Time frame: T1:One week before of starting treatment;T2: After 10 minutes of starting treatment;T3: After 1 week of starting treatment;T4: After 30 days of starting treatment;T5:After 6 months

  2. Clinical parameters: probing depth (PS)

    distance from the gingival margin to the fundus of the gingival sulcus or periodontal pocket, which will be measured by means of manual circumferential probing and measured on all the faces of the restored teeth and control;

    Time frame: T1:One week before of starting treatment;T2: After 10 minutes of starting treatment;T3: After 1 week of starting treatment;T4: After 30 days of starting treatment;T5:After 6 months;

  3. Clinical parameters: probing bleeding (SS)

    Bleeding to the Survey (SS): evaluated at the moment of PS measurement or until 30 to 60 seconds after the introduction of the probe with dichotomic values by presence (score 1) or absence (score 0)

    Time frame: T1:One week before of starting treatment;T2: After 10 minutes of starting treatment;T3: After 1 week of starting treatment;T4: After 30 days of starting treatment;T5:After 6 months

  4. Clinical parameters: gingival index (GI)

    evaluates the existence and severity of gingival lesions on a scale ranging from 0 to 3, where: 0: normal; 1. mild inflammation with color change, mild edema, no bleeding at probing; 2. moderate inflammation with red, shiny, swollen gingival tissue and presence of bleeding on probing; 3. severe inflammation, with great increase of color and edema, ulceration and tendency to spontaneous bleeding.

    Time frame: T1:One week before of starting treatment;T2: After 10 minutes of starting treatment;T3: After 1 week of starting treatment;T4: After 30 days of starting treatment;T5:After 6 months

07

Study locations

1 site
  • Federal University Of Minas Gerais
    Belo Horizonte, Minas Gerais 31270-901, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03637946
Lead sponsor
Federal University of Minas Gerais
Collaborators
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Fundação de Amparo à Pesquisa do estado de Minas Gerais
Responsible party
Tassiana Cançado Melo Sá (Principal Investigator, Federal University of Minas Gerais) — Principal investigator
First posted
Aug 20, 2018
Start date
Jun 1, 2018
Primary completion
Apr 1, 2019
Completion
Feb 1, 2020
Last update
Feb 5, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion